Physician profile
John Nakayama
NPI 1528266483
$193,882.43
in general payments reported to CMS, 2019-2025
18 companies · $51K in 2025
The $51K reported for 2025 was more than what 97% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $6,537 · 2021: $23K · 2022: $37K · 2023: $31K · 2024: $35K · 2025: $51K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $63K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $25K · Consulting Fee: $14K · Travel and Lodging: $11K · Food and Beverage: $4,018.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $63,196.56 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $24,968.75 |
| Consulting Fee | $13,512.50 |
| Travel and Lodging | $10,904.38 |
| Food and Beverage | $4,018.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $78,800.49 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $65,134.60 | 2019-2025 | Lynparza |
| Merck Sharp & Dohme LLC | $36,875.84 | 2019-2025 | Lynparza |
| Clovis Oncology, INC. | $6,688.37 | 2019-2022 | |
| Astrazeneca Uk Limited | $2,226.25 | 2023 | Enhertu |
| Illumina, INC. | $2,161.56 | 2023 | Oncology Testing |
| Abbvie INC. | $725.00 | 2025 | |
| Seagen INC. | $374.44 | 2022-2023 | |
| Myriad Genetic Laboratories, INC. | $280.49 | 2024 | Mychoice Cdx, Myrisk |
| Intuitive Surgical, INC. | $157.94 | 2019-2020 | |
| Pfizer INC. | $149.86 | 2024 | |
| Glaxosmithkline, LLC. | $107.42 | 2021 | |
| Genmab U.S., INC. | $87.46 | 2024 | Tivdak |
| Regeneron Pharmaceuticals, INC. | $80.74 | 2025 | Libtayo |
| Janssen Biotech, INC. | $16.93 | 2025 | Rybrevant |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $15.04 | 2025 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Nakayama listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.